• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    Immortagen Completes Series A Financing for Personalized Medicine

    Investing News Network
    Sep. 19, 2016 09:15PM PST
    Life Science Investing News

    Immortagen, Inc. announced that it has successfully completed its Series A financing.  Immortagen is a cutting edge cancer company that is developing genetic analysis tools for personalized medicine.  These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment.  Immortagen’s product pipeline fills a key gap as more …

    Immortagen, Inc. announced that it has successfully completed its Series A financing. Immortagen is a cutting edge cancer company that is developing genetic analysis tools for personalized medicine. These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment. Immortagen’s product pipeline fills a key gap as more and more patient tumors are sequenced, and genetic analysis of the data is required. Founded by a team of leading physician-researchers and complemented with proven management, Immortagen believes it will fill a key gap in the global oncology market.
    Related Files


    ImmortaPressFinl for Series A 8-1-16-1-2.docx
    This content was issued through the press release distribution service at Newswire.com. For more info visit: https://www.newswire.com
    To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/immortagen-inc-completes-series-a-financing-for-personalized-medicine-300330524.html
    SOURCE Immortagen, Inc.

    personalized medicinediagnostics companies
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×